Clinical Trials
7 trialsNCT03220477 2025-08-06
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04299113 2025-06-26
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02993991 2017-12-29
PRIMED-001
University Health Network, Toronto
Phase 1 Withdrawn
NCT00323934 2015-01-08
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Mirati Therapeutics Inc.
Phase 1 Completed
NCT00324129 2015-01-08
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
Mirati Therapeutics Inc.
Phase 1 Completed
NCT00324194 2015-01-08
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
Mirati Therapeutics Inc.
Phase 1 Completed
NCT00511576 2015-01-08
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Mirati Therapeutics Inc.
Phase 1 Terminated